Adherence and patients' experiences with the use of erlotinib in NSCLC treatment: The influence on plasma concentration and the exploration of factors affecting the use in daily practice

Adherence and patients' experiences with the use of erlotinib in NSCLC treatment: The influence on plasma concentration and the exploration of factors affecting the use in daily practice - Adherence and patients* experiences with erlotinib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33122

Enrollment

Registered

2009-05-19

Start date

2009-10-27

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell-lung cancer or lung cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: NSCLC patients starting with erlotinib

Exclusion criteria

Exclusion criteria: younger than 18 year

Design outcomes

Primary

Measure	Time frame
Adherence rate; a patient is adherent with the intake of 85% or more of the prescribed medication, the plasma concentration of erlotinib and the number and grade of side-effects.	—

Secondary

Measure	Time frame
Quality of life Attitude towards disease Beliefs and attitude towards medicines Percentage of dose adjustment and discontinuation	—

Countries

Netherlands

Outcome results